Clinical Trial Update: Immunogenicity and Safety of Sequential 2vHPV-9vHPV Vaccination in Girls Aged 9-14 Years [Phase 4]

View source ↗

Summary

This Phase 4 study assesses the immunogenicity and safety of sequential vaccination with the 2-valent and 9-valent HPV vaccines in girls aged 9–14 years, and is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection

Drugs mentioned

• Cervarix (human papillomavirus vaccine, bivalent)
• Gardasil 9 (Human papillomavirus vaccine, 9-valent)

Snippet

Sponsor: Zhejiang Provincial Center for Disease Control and Prevention | Conditions: HPV Infection | Phase 4 | Status: RECRUITING